Results 91 to 100 of about 67,058 (255)

RUNX1‐Driven CPXM1 Transcription Promotes Malignant Phenotypes and EMT in Gastric Cancer Cells

Cancer Science, EarlyView.
RUNX1 transcriptionally activates CPXM1, promotes EMT, and enhances the proliferation, invasion, and metastasis of gastric cancer cells. ABSTRACT Gastric cancer (GC) remains a leading cause of cancer‐related mortality worldwide, with current treatment strategies largely limited to surgery, chemotherapy, and targeted therapy.
Ping Jia, Fengming Xu, Tao Zhou, Pingping Wang, Huiping Chen, Jing Zhang, Xiaochen Yuan, Haoxun Xu, Yu Ouyang   +8 more
wiley   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source

Concurrent Howell–Jolly body‐like inclusions, Barr bodies and Döhle bodies in an immunosuppressed patient with sepsis

British Journal of Haematology, EarlyView.
Vandana Panakkal, Nana P. Matsumoto
wiley   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

Clinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams, Bonnie Grant, Richard Quinton, Channa N. Jayasena   +3 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Third Allogeneic Stem Cell Transplantation in Children: A Multicenter Analysis From the Spanish GETH‐TC Pediatric Group

European Journal of Haematology, EarlyView.
ABSTRACT Third allogeneic hematopoietic stem cell transplantation (HSCT3) is rarely performed in pediatric patients and is associated with high toxicity and mortality. Data on outcomes in this setting remain scarce. We conducted a retrospective multicenter study within the Spanish GETH‐TC Pediatric group including 29 children and adolescents who ...
Luisa Sisinni, Sara Vinagre Enríquez, Marta Villalon Herrera, Mercedes Plaza Fornieles, Iván López Torija, Andrea Urtasun Erburu, Laura Alonso García, Alexandra Regueiro García, Maria Trabazo del Castillo, Eduardo J. Bardón‐Cancho, Odelaisy León‐Triana, Carla Miñarro Chacón, José Luís Fuster Soler, Antonio Pérez‐Martínez, Pascual Balsalobre López, Marta Gonzalez‐Vicent, Cristina Díaz de Heredia, on behalf of the GETH‐TC Pediatric Working Group   +17 more
wiley   +1 more source

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials

British Journal of Haematology, EarlyView.
Jong Wook Lee, Kohei Hosokawa, Jun Ho Jang, Naoshi Obara, Masashi Sawa, Kensuke Usuki, Gaku Oshikawa, Masahiro Kizaki, Koji Nagafuji, Ting‐An Lin, Hitoshi Hanamoto, Yeung‐Chul Mun, Toshiro Kawakita, Kazunori Imada, June‐Won Cheong, Sung‐Soo Park, Takayuki Tabayashi, Masaru Gamou, Kenta Murotani, Hirohito Yamazaki   +19 more
wiley   +1 more source

Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment

European Journal of Haematology, EarlyView.
ABSTRACT Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low‐dose cytarabine, hydroxyurea, or supportive care, with
Antonella Bruzzese, Enrica Antonia Martino, Santino Caserta, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

#59. Effect of Biallelic TP53 Mutations in Changing the Subclassification of Myelodysplastic Neoplasm

Graduate Medical Education Research Journal
Mentor: Neha Gupta Program: Pathology - Hematopathology Type: Original Research Background: TP53 mutation confers a poor prognosis in myelodysplastic neoplasms (MDS).
Ketav Desai, Timothy Greiner, Weiwei Zhang, Lynette M. Smith, Neha Gupta   +4 more
doaj   +1 more source